Meta-analysis of 7 studies (596 adults) of loncastuximab tesirine monotherapy in relapsed/refractory DLBCL: pooled overall response 45.8%, complete response 18.8%, median PFS 5.2 months, median OS 9.0 months; grade ≥3 cytopenias common; heterogeneity high.
Meta-analysisn = 596
Gibran-Nunes et al. Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis